Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT in CAR-T and AlloSCT
NCT07509450Recruiting
- Sponsor
- University Health Network
- Start
- Jun 2026
- Primary completion
- Jun 2029
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Open-label trial of fecal microbiome transplant in B-cell lymphoma (BCL), acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by University Health Network. Primary endpoints: Feasibility of fecal microbiota transplantation at 2.5 years and Safety of fecal microbiota transplantation at 2.5 years. Started Jun 2026; status: recruiting.
02
Drugs
fecal microbiome transplant
03
Conditions
B-cell lymphoma (BCL)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07509450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07509450.